安進洽購歐洲藥廠(AMGN.US)Horizon進入後期階段
格隆匯12月12日丨據市場消息,美國安進藥廠(AMGN.US)洽購歐洲生物製藥廠Horizon Therapeutics(HRZN.US)進入後期階段,而法國賽諾菲(SNY.US)藥廠已經退出洽購。據悉雙方最快可能在週一達成協議,但消息人士也不排除談判最終破裂的可能。上月,市值約220億美元的Horizon表示,與安進、賽諾菲及強生分支Janssen Global Services洽商整間出售的可能性。賽諾菲週日表示,已經不再與Horizon有任何洽商,也無意向對方提交正式收購建議,因為交易價格未合乎集團目標。Janssen上週也表示,不再與Horizon有任何商討。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.